Agios Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Agios Pharmaceuticals seeks stockholder approval for director elections, executive compensation, and a 2,000,000 share increase to its 2023 Stock Incentive Plan.
NASDAQ
Agios Pharmaceuticals will hold its annual stockholders meeting on June 18, 2025, to vote on director elections, executive compensation, a stock incentive plan amendment, and the ratification of its accounting firm.
NASDAQ
Agios Pharmaceuticals is asking stockholders to approve an amendment to its 2023 Stock Incentive Plan to increase the number of shares available for issuance by 2,500,000.
NASDAQ
Agios Pharmaceuticals will hold its annual stockholders meeting on June 20, 2024, to elect directors, approve executive compensation, and ratify the appointment of its accounting firm.
NASDAQ
DEF 14A: Agios Pharmaceuticals Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals
Agios Pharmaceuticals will hold its annual stockholders meeting virtually on June 20, 2024, to vote on director elections, executive compensation, and auditor ratification.